Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models

Karen Wagner, Bora Inceoglu, Hua Dong, Jun Yang, Sung Hee Hwang, Paul Jones, Christophe Morisseau, Bruce D. Hammock

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Epoxy-fatty acids have been recognized as important cell signaling molecules with multiple biological effects including anti-nociception. The main degradation pathway of these signaling molecules is via the soluble epoxide hydrolase (sEH) enzyme. Inhibitors of sEH extend the anti-nociceptive effects of fatty acid epoxides. In this study two models of pain with different etiology, streptozocin induced type I diabetic neuropathic pain and lipopolysaccharide induced inflammatory pain were employed to test sEH inhibitors. A dose range of three sEH inhibitors with the same central pharmacophore but varying substituent moieties was used to investigate maximal anti-allodynic effects in these two models of pain. Inhibiting the sEH enzyme in these models successfully blocked pain related behavior in both models. The sEH inhibitors were more potent and more efficacious than celecoxib in reducing both diabetic neuropathic pain and lipopolysaccharide induced inflammatory pain. Because of their ability to block diabetic neuropathic pain sEH inhibition is a promising new approach to treat chronic pain conditions.

Original languageEnglish (US)
Pages (from-to)93-101
Number of pages9
JournalEuropean Journal of Pharmacology
Volume700
Issue number1-3
DOIs
StatePublished - Jan 30 2013

Fingerprint

Epoxide Hydrolases
Neuralgia
Pain
Celecoxib
Lipopolysaccharides
Fatty Acids
Aptitude
Nociception
Epoxy Compounds
Enzymes
Streptozocin
Chronic Pain

Keywords

  • Diabetic neuropathic pain
  • Epoxygenated fatty acid
  • Inflammatory pain
  • Nociception
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models. / Wagner, Karen; Inceoglu, Bora; Dong, Hua; Yang, Jun; Hwang, Sung Hee; Jones, Paul; Morisseau, Christophe; Hammock, Bruce D.

In: European Journal of Pharmacology, Vol. 700, No. 1-3, 30.01.2013, p. 93-101.

Research output: Contribution to journalArticle

Wagner, K, Inceoglu, B, Dong, H, Yang, J, Hwang, SH, Jones, P, Morisseau, C & Hammock, BD 2013, 'Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models', European Journal of Pharmacology, vol. 700, no. 1-3, pp. 93-101. https://doi.org/10.1016/j.ejphar.2012.12.015
Wagner, Karen ; Inceoglu, Bora ; Dong, Hua ; Yang, Jun ; Hwang, Sung Hee ; Jones, Paul ; Morisseau, Christophe ; Hammock, Bruce D. / Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models. In: European Journal of Pharmacology. 2013 ; Vol. 700, No. 1-3. pp. 93-101.
@article{3650bc4390bc44438ac538710eef3848,
title = "Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models",
abstract = "Epoxy-fatty acids have been recognized as important cell signaling molecules with multiple biological effects including anti-nociception. The main degradation pathway of these signaling molecules is via the soluble epoxide hydrolase (sEH) enzyme. Inhibitors of sEH extend the anti-nociceptive effects of fatty acid epoxides. In this study two models of pain with different etiology, streptozocin induced type I diabetic neuropathic pain and lipopolysaccharide induced inflammatory pain were employed to test sEH inhibitors. A dose range of three sEH inhibitors with the same central pharmacophore but varying substituent moieties was used to investigate maximal anti-allodynic effects in these two models of pain. Inhibiting the sEH enzyme in these models successfully blocked pain related behavior in both models. The sEH inhibitors were more potent and more efficacious than celecoxib in reducing both diabetic neuropathic pain and lipopolysaccharide induced inflammatory pain. Because of their ability to block diabetic neuropathic pain sEH inhibition is a promising new approach to treat chronic pain conditions.",
keywords = "Diabetic neuropathic pain, Epoxygenated fatty acid, Inflammatory pain, Nociception, Soluble epoxide hydrolase",
author = "Karen Wagner and Bora Inceoglu and Hua Dong and Jun Yang and Hwang, {Sung Hee} and Paul Jones and Christophe Morisseau and Hammock, {Bruce D.}",
year = "2013",
month = "1",
day = "30",
doi = "10.1016/j.ejphar.2012.12.015",
language = "English (US)",
volume = "700",
pages = "93--101",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models

AU - Wagner, Karen

AU - Inceoglu, Bora

AU - Dong, Hua

AU - Yang, Jun

AU - Hwang, Sung Hee

AU - Jones, Paul

AU - Morisseau, Christophe

AU - Hammock, Bruce D.

PY - 2013/1/30

Y1 - 2013/1/30

N2 - Epoxy-fatty acids have been recognized as important cell signaling molecules with multiple biological effects including anti-nociception. The main degradation pathway of these signaling molecules is via the soluble epoxide hydrolase (sEH) enzyme. Inhibitors of sEH extend the anti-nociceptive effects of fatty acid epoxides. In this study two models of pain with different etiology, streptozocin induced type I diabetic neuropathic pain and lipopolysaccharide induced inflammatory pain were employed to test sEH inhibitors. A dose range of three sEH inhibitors with the same central pharmacophore but varying substituent moieties was used to investigate maximal anti-allodynic effects in these two models of pain. Inhibiting the sEH enzyme in these models successfully blocked pain related behavior in both models. The sEH inhibitors were more potent and more efficacious than celecoxib in reducing both diabetic neuropathic pain and lipopolysaccharide induced inflammatory pain. Because of their ability to block diabetic neuropathic pain sEH inhibition is a promising new approach to treat chronic pain conditions.

AB - Epoxy-fatty acids have been recognized as important cell signaling molecules with multiple biological effects including anti-nociception. The main degradation pathway of these signaling molecules is via the soluble epoxide hydrolase (sEH) enzyme. Inhibitors of sEH extend the anti-nociceptive effects of fatty acid epoxides. In this study two models of pain with different etiology, streptozocin induced type I diabetic neuropathic pain and lipopolysaccharide induced inflammatory pain were employed to test sEH inhibitors. A dose range of three sEH inhibitors with the same central pharmacophore but varying substituent moieties was used to investigate maximal anti-allodynic effects in these two models of pain. Inhibiting the sEH enzyme in these models successfully blocked pain related behavior in both models. The sEH inhibitors were more potent and more efficacious than celecoxib in reducing both diabetic neuropathic pain and lipopolysaccharide induced inflammatory pain. Because of their ability to block diabetic neuropathic pain sEH inhibition is a promising new approach to treat chronic pain conditions.

KW - Diabetic neuropathic pain

KW - Epoxygenated fatty acid

KW - Inflammatory pain

KW - Nociception

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=84872512484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872512484&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2012.12.015

DO - 10.1016/j.ejphar.2012.12.015

M3 - Article

VL - 700

SP - 93

EP - 101

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -